Search results
Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?
Zacks via Yahoo Finance· 7 months agoThe mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock....
Wall Street Analysts Trim Price Targets for These 10 Stocks
Insider Monkey via Yahoo Finance· 10 months agoIn this article, we will discuss the 10 stocks whose price targets were recently trimmed by...
Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 97% Above Its Share Price
Simply Wall St. via Yahoo Finance· 7 months agoKey Insights The projected fair value for Biogen is US$508 based on 2 Stage Free Cash Flow to Equity...
Biogen upgraded, Take-Two downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 6 months agoBiogen upgraded, Take-Two downgraded: Wall Street's top analyst calls The most talked about and...
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
Motley Fool via Yahoo Finance· 3 months agoOn Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen,...
Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump
Investor's Business Daily· 12 months agoBiogen stock jumped into a buy zone Thursday after Medicare officials said they would reimburse...
Biogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key Endorsement
Investor's Business Daily· 1 year agoBiogen stock jumped — as Ionis stock gave back early gains — after a Food and Drug Administration...
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
Investor's Business Daily· 2 years agoBiogen could easily take on Roche and Eli Lilly in Alzheimer's treatment, an analyst said Thursday...
Biogen Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Simply Wall St. via Yahoo Finance· 3 months agoShareholders might have noticed that Biogen Inc. (NASDAQ:BIIB) filed its full-year result this time...
Better Alzheimer's Disease Stock: Eli Lilly or Biogen?
Motley Fool· 2 years agoSeveral big-name companies are racing to develop effective therapies for Alzheimer's disease (AD), a...